Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)
Crossref DOI link: https://doi.org/10.1007/s11912-016-0522-0
Published Online: 2016-05-02
Published Print: 2016-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Crawford, Jeffrey
Prado, Carla M. M.
Johnston, Mary Ann
Gralla, Richard J.
Taylor, Ryan P.
Hancock, Michael L.
Dalton, James T.
License valid from 2016-05-02